Essange Reagents is an international developer and manufacturer of in vitro diagnostics (IVD) reagents with an extensive product portfolio of hematology and immune reagents.

Owing to its extensive history in blood research, Essange Reagents stands out in the healthcare landscape, as it produces tests that are offered by only a handful of other providers, making its diagnostics significantly impactful in enhancing patient outcomes. Its high-quality standards, adhered to by a team of experts, enable the company to build long-lasting customer relationships with leading global IVD players.

Immune reagents are a crucial tool in the diagnosis of several conditions, including autoimmune disorders, bone marrow cancer, and recurrent infections. Earlier diagnoses from comprehensive tests not only helps patients in their symptom control but also increases survival rates.

Gilde Healthcare acquired a majority share in 2022 and will support Essange Reagents’ management team in realizing its growth and development ambitions. With this investment, Gilde aims to make a positive impact on the health of patients by increasing the availability of complex niche hematology and immunology tests.